zifeng-ai/TrialReviewBench huggingface dataset:
Study: Sun/2021 (KEYNOTE590/randomized)
Ethnicity: Asian and non
Number of participants: 373 versus 376
CPS >=10/PD-L1 >=1: 143 versus 143b/NA
Line of therapy: 1st
Histology: ESCC & ADK
Treatments used in each arm: PEMBRO + CT versus CT alone
ORR (%): --
PFS (HR, 95%CI): 0.65 (0.54-0.78)b
OS (HR, 95%CI): 0.72 (0.60-0.88)b
Risk of bias: Low
Study: Kojima/2020 (KEYNOTE181/randomized)
Ethnicity: Asian and non
Number of participants: 314 versus 314
CPS >=10/PD-L1 >=1: 85 versus 82b/NA
Line of therapy: 2nd
Histology: ESCC & ADK
Treatments used in each arm: PEMBRO versus CT (investigator's choice)
ORR (%): 16.7 versus 7.4b
PFS (HR, 95%CI): 0.92 (0.75-1.13)b
OS (HR, 95%CI): 0.75 (0.61-0.93)b
Risk of bias: Low
Study: Kato/2019 (ATTRACTION3/randomized)
Ethnicity: Asian and non
Number of participants: 210 versus 209
CPS >=10/PD-L1 >=1: NA/101 versus 102e
Line of therapy: 2nd
Histology: ESCC
Treatments used in each arm: NIVO versus CT (investigator's choice)
ORR (%): 19 versus 22
PFS (HR, 95%CI): 1.08 (0.87-1.34)
OS (HR, 95%CI): 0.77 (0.62-0.96)
Risk of bias: Low
Study: Chau/2021 (CHECKMATE648a/randomized)
Ethnicity: Asian and non
Number of participants: 321 versus 325 versus 324
CPS >=10/PD-L1 >=1: NA/158 versus 158 versus 157e
Line of therapy: 1st
Histology: ESCC
Treatments used in each arm: NIVO + CT versus NIVO + IPI versus CT alone
ORR (%): 47 versus 27c28 versus 27d
PFS (HR, 95%CI): 0.81 (0.64-1.04)c1.26 (1.04-1.52)d
OS (HR, 95%CI): 0.74 (0.58-0.96)c0.78 (0.62-0.98)d
Risk of bias: Moderate
Study: Shen/2021 (ORIENT15a/randomized)
Ethnicity: Asian
Number of participants: 327 versus 332
CPS >=10/PD-L1 >=1: 188 versus 193/NA
Line of therapy: 1st
Histology: ESCC
Treatments used in each arm: Sintilimab + CT versus CT alone
ORR (%): 66.1 versus 45.5
PFS (HR, 95%CI): 0.55 (0.46-0.67)
OS (HR, 95%CI): 0.62 (0.50-0.77)
Risk of bias: Moderate
Study: Xu/2021 (JUPITER06a/randomized)
Ethnicity: Asian
Number of participants: 257 versus 257
CPS >=10/PD-L1 >=1: 115 versus 97/201 versus 200f
Line of therapy: 1st
Histology: ESCC
Treatments used in each arm: Toripalimab + CT versus CT alone
ORR (%): --
PFS (HR, 95%CI): 0.58 (0.46-0.74)
OS (HR, 95%CI): 0.58 (0.43-0.78)
Risk of bias: Moderate
Study: Huang/2020 (ESCORT/randomized)
Ethnicity: Asian
Number of participants: 228 versus 220
CPS >=10/PD-L1 >=1: NA/26 versus 35e
Line of therapy: 2nd
Histology: ESCC
Treatments used in each arm: Camrelizumab versus CT
ORR (%): 20.2 versus 6.4
PFS (HR, 95%CI): 0.69 (0.56-0.86)
OS (HR, 95%CI): 0.71 (0.57-0.88)
Risk of bias: Low
Study: Shen/2021 (RATIONALE302a/randomized)
Ethnicity: Asian and non
Number of participants: 256 versus 256
CPS >=10/PD-L1 >=1: 89 versus 68/NA
Line of therapy: 2nd
Histology: ESCC
Treatments used in each arm: Tislelizumab versus CT
ORR (%): 20.3 versus 9.8
PFS (HR, 95%CI): 0.83 (0.67-1.01)
OS (HR, 95%CI): 0.70 (0.57-0.85)
Risk of bias: Moderate
Study: Luo/2021 (ESCORT-1st/randomized)
Ethnicity: Asian
Number of participants: 298 versus 298
CPS >=10/PD-L1 >=1: NA/104 versus 98e
Line of therapy: 1st
Histology: ESCC
Treatments used in each arm: Camrelizumab + CT versus CT alone
ORR (%): 72.1 versus 62.1
PFS (HR, 95%CI): 0.56 (0.46-0.68)
OS (HR, 95%CI): 0.70 (0.56-0.88)
Risk of bias: Low
Study: Xu/2020 (ORIENT2a/randomized)
Ethnicity: Asian
Number of participants: 95 versus 95
CPS >=10/PD-L1 >=1: --
Line of therapy: 2nd
Histology: ESCC
Treatments used in each arm: Sintilimab versus CT
ORR (%): 12.6 versus 6.3
PFS (HR, 95%CI): 1.00 (0.77-1.39)
OS (HR, 95%CI): 0.70 (0.50-0.97)
Risk of bias: Moderate